FDA proposes wider patient access to experimental drugs

14

Mar
2007

The U.S. Food and Drug Administration (FDA) has proposed regulatory changes to provide seriously ill patients without other treatment options with easier access to experimental drugs. Before such drugs are made available to patients in such circumstances, the FDA would first need to be satisfied that the potential benefits of such drugs outweigh their risks. For more information, go to www.fda.gov/bbs/topics/NEWS/2006/NEW01520.html

email this page print this page permanent link

Related News

Baron & Budd, P.C.:
Since 1977, the law firm of Baron & Budd, P.C. has championed the rights of people and communities harmed by corporate misconduct. With over 50 attorneys and offices in Texas, California, and Louisiana, Baron & Budd enjoys a national reputation as a leader of the plaintiffs’ bar. The firm represents individuals with mesothelioma and other diseases caused by asbestos and injuries caused by other toxic substances and pharmaceuticals. The firm also represents water authorities seeking clean-up costs for drinking water contamination; securities investors and governmental entities defrauded by corporate wrongdoing; and consumers. For more information about Baron & Budd, call 800-222-2766 or contact us via our secure form.

 
Other Offices:
  • Baton Rouge, LA
  • Cleveland, OH
  • Beverly Hills, CA
  • Austin, TX
Main Office:
3102 Oak Lawn Avenue, Suite 1100
Dallas, TX 75219
For nearly 30 years, the law firm of Baron & Budd, P.C. has fought to safeguard the rights of mesothelioma victims and their families. MesotheliomaNews.com is a public service of Baron & Budd, P.C.

© 2008, Baron & Budd, P.C.